BMRN - Biomarin Pharmaceutical - Stock & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US09061G1013
Enzyme Replacement Therapies, Proteins, Enzymes, Injections, Medications
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California. Web URL: https://www.biomarin.com
Drawdown (Underwater) Chart
![Drawdown / Underwater Chart for BMRN - Biomarin Pharmaceutical - Stock & Dividends](https://www.valueray.com/images/drawdown_chart/BMRN.NASDAQ_drawdown.png)
Overall Trend and Yearly Seasonality
![Drawdown / Underwater Chart for BMRN - Biomarin Pharmaceutical - Stock & Dividends](https://www.valueray.com/images/chart/BMRN.NASDAQ_seasonality.png)
BMRN Stock Overview
Market Cap in USD | 15,825m |
Sector | Healthcare |
Industry | Biotechnology |
GiC SubIndustry | Biotechnology |
TER | 0.00% |
IPO / Inception | 1999-07-23 |
BMRN Stock Ratings
Growth 5y | 4.74 |
Fundamental | 34.6 |
Dividend | 0.00 |
Rel. Performance vs Sector | -1.85 |
Analysts | 4.19/5 |
Fair Price Momentum | 76.86 USD |
Fair Price DCF | 22.66 USD |
BMRN Dividends
Dividend Yield 12m | 0.00% |
Yield on Cost 5y | 0.00% |
Dividends CAGR 5y | 0.00% |
Payout Consistency | 0.0% |
BMRN Growth Ratios
Growth 12m | -3.45% |
Growth Correlation 12m | -34% |
Growth Correlation 3m | 38% |
CAGR 5y | 1.16% |
CAGR/Mean DD 5y | 0.04 |
Sharpe Ratio 12m | -0.32 |
Alpha vs SP500 12m | -19.33 |
Beta vs SP500 5y weekly | 0.68 |
ValueRay RSI | 62.83 |
Volatility GJR Garch 1y | 27.63% |
Price / SMA 50 | 3.63% |
Price / SMA 200 | -2.48% |
Current Volume | 1063.4k |
Average Volume 20d | 1315.9k |
External Links for BMRN Stock
News
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
What is the price of BMRN stocks?
As of July 27, 2024, the stock is trading at USD 84.59 with a total of 1,063,391 shares traded.
Over the past week, the price has changed by +0.59%, over one month by -0.77%, over three months by +4.55% and over the past year by -3.80%.
As of July 27, 2024, the stock is trading at USD 84.59 with a total of 1,063,391 shares traded.
Over the past week, the price has changed by +0.59%, over one month by -0.77%, over three months by +4.55% and over the past year by -3.80%.
What are the forecast for BMRN stock price target?
According to ValueRays Forecast Model, BMRN Biomarin Pharmaceutical will be worth about 84.6 in July 2025. The stock is currently trading at 84.59. This means that the stock has a potential downside of -0.02%.
According to ValueRays Forecast Model, BMRN Biomarin Pharmaceutical will be worth about 84.6 in July 2025. The stock is currently trading at 84.59. This means that the stock has a potential downside of -0.02%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 108.2 | 27.9 |
Analysts Target Price | 117 | 38.3 |
ValueRay Target Price | 84.6 | -0.02 |